| Short Description : | Recombinant-2019 nCoV/COVID19 Nucleocapsid-His-Tag protein was developed from cho cells and has a target region of His-Tag. For use in research applications. |
| Host: | CHO Cells |
| Note: | STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Conjugation: | Unconjugated |
| Dilution Range: | Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Formulation: | Lyophilised from 0.2 µm filtered PBS, pH 7.4. |
| Storage Instruction: | The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. NA |
| Endotoxin: | Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunogen: | DNA sequence encoding the COVID-19 Nucleocapsid protein domain, amino acids[1-419] (accession# YP_009724397.2) including a C-terminal His tag was expressed in CHO Cells. NA |
| Immunogen Region: | 1-419 aa |
| Background | Recombinant 2019-nCoV Nucleocapsid protein is a protein consisting of 431 amino acid residues, due to glycosylation migrates as an approximately 70 kDa protein on SDS-PAGE. |
Information sourced from Uniprot.org
